Sign in
Taking peoplePhase 2

SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .

Key facts

Who runs it
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
360 people, planned
Started
11 Aug 2026
Expected to end
31 Oct 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SYH2062
  • Placebo
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • ≥18 years of age, male or female at the time of signing the ICF
  • Body mass index range of 18.0 ≤ BMI ≤ 37.5 kg/m2
  • Untreated / Currently receiving 1-2 antihypertensive medications
  • Blood pressure in the clinic during the screening period or before randomization meets 130 ≤ SBP < 170 mmHg, DBP < 110 mmHg
  • Ambulatory blood pressure during the screening period meets 130 mmHg ≤ mSBP
  • Participants are able to communicate well with the researchers and complete the trial according to the protocol

Who cannot take part

  • Severe cardiovascular or cerebrovascular disease within 6 months prior to screening
  • History of severe arrhythmia within 6 months prior to screening
  • Malignant tumor within 5 years prior to screening, except for tumors expected to be curable after treatment (such as completely excised basal cell carcinoma or squamous cell carcinoma of the skin, etc.)
  • Underwent major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period
  • Allergy to any component of the study drug; or a clinically significant history of severe allergy
  • Hypertension and secondary hypertension in special populations
  • History of orthostatic hypotension
  • When screening, ALT and AST > 2 times the upper limit of normal, or total bilirubin and direct bilirubin > 1.5 times the upper limit of normal
  • Estimated eGFR at screening < 30 mL/min/1.73 m2
  • Serum potassium level at screening > 5 mmol/L

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mild to moderate primary hypertension

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This phase II clinical trial, involving multiple subcutaneous injections, aimed to evaluate the efficacy, safety, pharmacokinetic (PK), PD, and immunogenicity characteristics of SYH2062 injection in patients with mild to moderate essential hypertension.

The 2 groups in the trial

  • SYH 2062 InjectionTreatment being tested

    Treatment: SYH2062

  • PlaceboPlacebo, for comparison

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension.
Criteria questions
Built from NCT07940075, who can take part
Record updated
16 November 2026